Statin therapy has now been shown to reduce the incidence of adverse cardiovascular events and mortality in individuals without overt signs of cardiovascular disease but with risk factors, which ...

Use of statins was cost-effective with the cost per QALY gained below £3502 for standard therapy and below £11,778 for higher intensity therapy, which is well under the current threshold for ...

Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...

ATP = Adult Treatment Panel; BAR = bile acid resin; BMI = body mass index; CHD = coronary heart disease; CVA = cerebral vascular accident; HDL-C = high-density lipoprotein cholesterol. a n = 44.

Concerns about the potential toxic effects of high-dose statins in patients with renal ... lipid-lowering treatment is both safe and effective in this high-risk population.

The polypill offers a cost-effective solution for CVD management in underserved populations, potentially reducing health disparities. The intervention is projected to cost $8560 per QALY gained ...

In a second paper, I and a colleague described the deceptive approach statin advocates have used to exaggerate the appearance of the effectiveness of statins in reducing coronary events.